6-氯-2-氰基-3-硝基吡啶 | 93683-65-9

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 中文名称: 6-氯-2-氰基-3-硝基吡啶
• 中文别名: 2-氰基-3-硝基-6-氯吡啶
• 英文名称: 6-chloro-3-nitropicolinonitrile
• 英文别名: 6-Chloro-3-nitro-pyridine-2-carbonitrile；2-cyano-3-nitro-6-chloropyridine；6-chloro-3-nitropyridine nitrile；6-chloro-2-cyano-3-nitropyridine；6‐chloro‐2‐cyano‐3‐nitropyridine；6-chloro-3-nitropyridine-2-carbonitrile
• CAS: 93683-65-9
• 化学式: C₆H₂ClN₃O₂
• mdl: MFCD06657641
• 分子量: 183.554
• InChiKey: XVIHGTRTKQZJAC-UHFFFAOYSA-N

物化性质

• 熔点：
  118-120 °C
• 沸点：
  347.2±42.0 °C(Predicted)
• 密度：
  1.57±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  82.5
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  T
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  | 室温 干燥 |

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Chloro-2-cyano-3-nitropyridine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Chloro-2-cyano-3-nitropyridine
CAS number: 93683-65-9

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H2ClN3O2
Molecular weight: 183.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

概述

6-氯-2-氰基-3-硝基吡啶是吡啶类衍生物，可作为医药中间体使用。

反应信息

• 作为反应物：
  描述：

  6-氯-2-氰基-3-硝基吡啶 在 四(三苯基膦)钯 、 stannous chloride decahydrate 、 potassium carbonate 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 氘代乙腈 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 24.5h， 生成 N-(3-(2-chloro-4-morpholinopyrido[3,2-d]pyrimidin-6-yl)-2-fluorophenyl)propane-1-sulfonamide
  参考文献：
  名称：

  [EN] QUINAZOLINES AND AZAQUINAZOLINES AS DUAL INHIBITORS OF RAS/RAF/MEK/ERK AND PI3K/AKT/PTEN/MTOR PATHWAYS
  [FR] QUINAZOLINES ET AZAQUINAZOLINES EN TANT QUE DOUBLES INHIBITEURS DES VOIES RAS/RAF/MEK/ERK ET PI3K/AKT/PTEN/MTOR

  摘要：

  本申请提供了新型喹唑啉和氮杂喹唑啉及其药用可接受盐。还提供了制备这些化合物的方法。通过向患者投与式有效量的式(I)化合物中的一个或多个，其中X、Y、T和R4，以及R6到R8'在此处定义，来共同调节RAS/RAF/MEK/ERK和PI3K/AKT/PTEN/mTOR途径。通过这样做，这些化合物在治疗与RAS/RAF/MEK/ERK和PI3K/AKT/PTEN/mTOR途径失调相关的疾病方面是有效的。可以使用这些化合物治疗各种疾病，包括以异常细胞增殖为特征的疾病。在一个实施例中，该疾病是癌症。

  公开号：

  WO2014169167A1
• 作为产物：
  描述：

  2,6-二氯吡啶 在 N-甲基吡咯烷酮 、 硫酸 、 硝酸 作用下， 反应 6.0h， 生成 6-氯-2-氰基-3-硝基吡啶
  参考文献：
  名称：

  Mnk1/2抑制剂4-(吲哚啉-1-基)-6-取代-吡啶并[3,2-d]嘧啶衍生物的设计、合成和生物学评价

  摘要：

  Mnk-eIF4E 轴在肿瘤发展中起着至关重要的作用，抑制 Mnk 激酶是一种有前景的癌症治疗方法。从片段开始，设计并合成了一系列4-(二氢吲哚-1-基)-6-取代-吡啶并[3,2-]嘧啶衍生物。在这些衍生物中，化合物对 Mnk1 和 Mnk2 显示出最高的效力，IC 值分别为 0.8 和 1.5 nM。此外，它在 30 种选定的激酶中表现出良好的选择性。显着抑制 MOLM-13 和 K562 细胞系生长并导致细胞周期停滞。此外，Western blot 检测显示，有效下调下游蛋白 -eIF4E、Mcl-1 和 c-myc。此外，在大鼠血浆以及大鼠和人类微粒体中表现出显着的稳定性。抗肿瘤活性研究表明，在 LL/2 同基因模型中，治疗可抑制肿瘤生长。这些发现凸显了 Mnks 作为新型有效抑制剂的潜力，值得进一步研究。

  DOI：

  10.1016/j.ejmech.2024.116499

文献信息

• Bicyclic compounds capable of inhibiting tyrosine kinases of the
  申请人：Warner-Lambert Company

  公开号：US05654307A1

  公开（公告）日：1997-08-05

  Novel 4-substituted amino pyrido pyrimidine and 4-substituted amino pyrido pyrimidine inhibitors of epidermal growth factor receptor family of tyrosine kinase are described, as well as pharmaceutical compositions of the same, which are useful in treating proliferative diseases such as cancer, synovial pannus invasion in arthritis, psoriasis, vascular restenosis and angiogenesis and additionally useful in the treatment of pancreatitis and kidney disease as well as a contraceptive agent.

  描述了新型4-取代氨基吡啶嘧啶和4-取代氨基吡啶嘧啶抑制剂对表皮生长因子受体家族的酪氨酸激酶的作用，以及相应的药物组合物，这些药物在治疗癌症、关节炎中的滑膜侵袭、牛皮癣、血管再狭窄和血管生成方面非常有用，此外还可用于治疗胰腺炎和肾病，以及作为避孕药剂。
• Structure-activity relationship study of the pyridine moiety of isothiazolo[4,3-b]pyridines as antiviral agents targeting cyclin G-associated kinase
  作者：Belén Martinez-Gualda、Szu-Yuan Pu、Mathy Froeyen、Piet Herdewijn、Shirit Einav、Steven De Jonghe

  DOI：10.1016/j.bmc.2019.115188

  日期：2020.1

  promising antiviral activity. In this manuscript, the structure-activity relationship study was expanded to synthesis of isothiazolo[4,3-b]pyridines with modifications of the pyridine moiety. This effort led to the discovery of an isothiazolo[4,3-b]pyridine derivative with a 3,4-dimethoxyphenyl residue at position 5 that displayed low nanomolar GAK binding affinity and antiviral activity against dengue

  以前，我们报道了3,6-二取代异噻唑并[4,3-b]吡啶的发现，它是有效的和选择性的细胞周期蛋白G相关激酶（GAK）抑制剂，具有有希望的抗病毒活性。在该手稿中，结构-活性关系研究扩展到合成具有吡啶部分修饰的异噻唑并[4,3-b]吡啶。这项工作导致发现了在位置5具有3,4-二甲氧基苯基残基的异噻唑并[4,3-b]吡啶衍生物，该衍生物显示出低的纳摩尔GAK结合亲和力和抗登革热病毒的抗病毒活性。
• DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE AS MEDICAMENT
  申请人：PIERRE FABRE MEDICAMENT

  公开号：US20130085144A1

  公开（公告）日：2013-04-04

  The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; as well as to the use of same as a drug, notably intended for the treatment of cancer, inflammation and neurodegenerative diseases such as Alzheimer's disease; to the use of same as a kinase inhibitor; to the pharmaceutical compositions comprising same; and to methods for the preparation of same.

  本发明涉及以下式（I）的化合物： 或其药学上可接受的盐或溶剂，同分异构体，立体异构体或同分异构体的混合物，比如对映体混合物，尤其是消旋混合物；以及将其用作药物，尤其是用于治疗癌症、炎症和神经退行性疾病如阿尔茨海默病；将其用作激酶抑制剂；含有同样化合物的药物组合物；以及制备同样化合物的方法。
• [EN] DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING PAIN<br/>[FR] DÉRIVÉS DE TYPE AZA-INDAZOLE OU DIAZA-INDAZOLE POUR LE TRAITEMENT DE LA DOULEUR
  申请人：PF MEDICAMENT

  公开号：WO2014016433A1

  公开（公告）日：2014-01-30

  The present invention relates to a compound of following formula (I): or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain.

  本发明涉及如下式(I)的化合物：或其药用可接受的盐或溶剂化物，其构象异构体，或其立体异构体或立体异构体混合物，以任何比例，例如对映体混合物，尤其是外消旋混合物；用于治疗疼痛。
• [EN] DERIVATIVES OF AZAINDAZOLE OR DIAZAINDAZOLE TYPE FOR TREATING A CANCER OVEREXPRESSING TRK<br/>[FR] DÉRIVÉS DE TYPE AZA-INDAZOLE OU DIAZA-INDAZOLE POUR LE TRAITEMENT D'UN CANCER SUREXPRIMANT LA TRK
  申请人：PF MEDICAMENT

  公开号：WO2014016434A1

  公开（公告）日：2014-01-30

  The present invention relates to a compound of following formula (I) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture, as well as pharmaceutical composition comprising such a compound, for use in the treatment of a cancer associated with the overexpression of at least one Trk protein.

  本发明涉及式(I)所示的化合物，或其药用可接受的盐或溶剂化物，其同分异构体，或其立体异构体或立体异构体混合物，以任何比例，例如对映体混合物，尤其是外消旋混合物，以及包含该化合物的药物组合物，用于治疗与至少一种Trk蛋白过表达相关的癌症。